05892791001
Roche
cOmplete™ ULTRA Tablets, Mini, EDTA-free, EASYpack Protease Inhibitor Cocktail
Tablets supplied in foil blister packs.
Synonim(y):
protease inhibitor
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Kod UNSPSC:
12352204
NACRES:
NA.21
Polecane produkty
Postać
tablet
opakowanie
pkg of 30 tablets (individually packed in foil blister packs)
producent / nazwa handlowa
Roche
metody
immunoblotting: suitable
western blot: suitable
rozpuszczalność
water: soluble
absorpcja
0.4 at 280 nm (1x solution)
temp. przechowywania
2-8°C
Opis ogólny
Recombinant proteins may be partially degraded during expression. Soluble degradation products are co-purified and cause a non-homogeneous protein preparation with protein fragments of different lengths. However, metalloproteases are prevalent in (for example) bacteria and some techniques require that EDTA be omitted.
cOmplete ULTRA Tablets, Mini, EDTA-free contain the most powerful protease inhibitor cocktail for the optimal protection of your proteins against protease degradation. They are supplied as tablets in an EASYpack blister pack. EASYpacks provide the most convenient form of delivery - single tablets are easily pushed through the blister foil directly into the buffer. One cOmplete ULTRA Tablet, Mini, EDTA-free is sufficient for a volume of 10 ml extraction solution.
cOmplete ULTRA Tablets, Mini, EDTA-free are identical to cOmplete ULTRA Tablets, Mini, the only difference being that no EDTA or other chelating agents (e.g. EGTA) are included.
cOmplete ULTRA Tablets, Mini, EDTA-free contain the most powerful protease inhibitor cocktail for the optimal protection of your proteins against protease degradation. They are supplied as tablets in an EASYpack blister pack. EASYpacks provide the most convenient form of delivery - single tablets are easily pushed through the blister foil directly into the buffer. One cOmplete ULTRA Tablet, Mini, EDTA-free is sufficient for a volume of 10 ml extraction solution.
cOmplete ULTRA Tablets, Mini, EDTA-free are identical to cOmplete ULTRA Tablets, Mini, the only difference being that no EDTA or other chelating agents (e.g. EGTA) are included.
Specyficzność
Inhibits serine proteases, cysteine proteases, and aspartic proteases. Does not inhibit metalloproteases.
Zastosowanie
During cell lysis and purification, target proteins are at risk of being cleaved by proteases, which are naturally present in cells. To ensure that full-length proteins are obtained, cOmplete™ ULTRA Tablets are used for the inhibition of an extended range of proteases. This new formulation shows highest inhibition ratios due to its broadened range of inhibitors compared to standard cOmplete Tablets.
This new protease inhibitor cocktail now inhibits aspartic proteases, as well as serine and cysteine proteases. cOmplete ULTRA Tablets were developed for maximum efficiency on different cell types. Best performance is guaranteed in lysates of bacteria, yeast, insect cells, and a wide range of higher cell lines.
This tablet does not contain EDTA; therefore, metalloproteases are not inhibited.
For the purification of histidine-tagged proteins using Immobilized Metal Ion Affinity Chromatography (IMAC), this EDTA-free tablet is recommended for applications using non-EDTA compatible IMAC resins. Alternatively, an EDTA-containing cOmplete ULTRA, Mini tablet may be used in combination with Roche ′s new EDTA-compatible chromatography material, cOmplete His-Tag Purification Resin.
This new protease inhibitor cocktail now inhibits aspartic proteases, as well as serine and cysteine proteases. cOmplete ULTRA Tablets were developed for maximum efficiency on different cell types. Best performance is guaranteed in lysates of bacteria, yeast, insect cells, and a wide range of higher cell lines.
This tablet does not contain EDTA; therefore, metalloproteases are not inhibited.
For the purification of histidine-tagged proteins using Immobilized Metal Ion Affinity Chromatography (IMAC), this EDTA-free tablet is recommended for applications using non-EDTA compatible IMAC resins. Alternatively, an EDTA-containing cOmplete ULTRA, Mini tablet may be used in combination with Roche ′s new EDTA-compatible chromatography material, cOmplete His-Tag Purification Resin.
cOmplete™ ULTRA Tablets, Mini, EDTA-free, EASYpack Protease Inhibitor Cocktail has been used as a component of
- homogenization buffer for muscle samples for immunoblotting sample preparation
- radioimmunoprecipitation assay buffer (RIPA buffer) for protein extraction from brain samples for western blotting
- lysis buffer for the human embryonic kidney 293 (HEK293) lysate preparation for western blotting
Cechy i korzyści
- Protect your precious proteins.
- Why settle for less.
- Defend against a broad range of proteases.
- Convenient and safe tablet format.
Komponenty
Proprietary mixture of several protease inhibitors with broad inhibitory specificity.
Postać fizyczna
Tablets in foil blister packs. Each tablet is sufficient for a volume of 10 ml extraction solution.
Uwaga dotycząca przygotowania
Working concentration: 1 tablet per 10 ml extraction solution
Working solution: Handling
Carefully push the tablet through the foil packaging using the base of your thumb (not your fingernail) to prevent the breakage of tablets.
Preparation of Working Solution
One tablet is sufficient for the inhibition of proteolytic activity in 10 ml extraction solution. If very high proteolytic activity is present, 2-3 tablets should be used for 10 ml extraction buffer. The tablets can be added directly to the extraction medium.
Stock Solution (2x conc.)
Alternatively to the direct use with lysates, a 2x stock solution can be prepared, with the following procedure:
• Add one cOmplete ULTRA Tablet, Mini, EDTA-free to 5 ml double-distilled water in a PE or PP tube.
• Vortex 3 min or until the tablet is completely dissolved.
• The stock solution is ready to use even if there are very fine particles still visible in solution. These particles do not interfere with the inhibition performance of the tablets.
• This stock solution is stable for 4 weeks, stored at 2 to 8 °C, and for at least 4 weeks at -15 to -25 °C as well.
• During storage of the 2x stock solution, the particles can sediment. Briefly vortex the stock solution prior to use.
Storage conditions (working solution): The stock solution in water is stable for 4 weeks, stored at 2 to 8 °C, and for at least 4 weeks at -15 to -25 °C as well.
Working solution: Handling
Carefully push the tablet through the foil packaging using the base of your thumb (not your fingernail) to prevent the breakage of tablets.
Preparation of Working Solution
One tablet is sufficient for the inhibition of proteolytic activity in 10 ml extraction solution. If very high proteolytic activity is present, 2-3 tablets should be used for 10 ml extraction buffer. The tablets can be added directly to the extraction medium.
Stock Solution (2x conc.)
Alternatively to the direct use with lysates, a 2x stock solution can be prepared, with the following procedure:
• Add one cOmplete ULTRA Tablet, Mini, EDTA-free to 5 ml double-distilled water in a PE or PP tube.
• Vortex 3 min or until the tablet is completely dissolved.
• The stock solution is ready to use even if there are very fine particles still visible in solution. These particles do not interfere with the inhibition performance of the tablets.
• This stock solution is stable for 4 weeks, stored at 2 to 8 °C, and for at least 4 weeks at -15 to -25 °C as well.
• During storage of the 2x stock solution, the particles can sediment. Briefly vortex the stock solution prior to use.
Storage conditions (working solution): The stock solution in water is stable for 4 weeks, stored at 2 to 8 °C, and for at least 4 weeks at -15 to -25 °C as well.
Rekonstytucja
Soluble in aqueous buffers, or add directly to extraction media. For the stock solution, use water only.
Inne uwagi
For life science research only. Not for use in diagnostic procedures.
Informacje prawne
cOmplete is a trademark of Roche
This page may contain text that has been machine translated.
Hasło ostrzegawcze
Danger
Zwroty wskazujące rodzaj zagrożenia
Zwroty wskazujące środki ostrożności
Klasyfikacja zagrożeń
Aquatic Chronic 3 - Eye Dam. 1 - Skin Corr. 1B
Kod klasy składowania
8A - Combustible, corrosive hazardous materials
Klasa zagrożenia wodnego (WGK)
WGK 2
Temperatura zapłonu (°F)
does not flash
Temperatura zapłonu (°C)
does not flash
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Klienci oglądali również te produkty
Tony E R Werner et al.
Proceedings of the National Academy of Sciences of the United States of America, 117(45), 27997-28004 (2020-10-24)
Amyloid formation involves the conversion of soluble protein species to an aggregated state. Amyloid fibrils of β-parvalbumin, a protein abundant in fish, act as an allergen but also inhibit the in vitro assembly of the Parkinson protein α-synuclein. However, the
Pearl Lee et al.
Nature communications, 11(1), 498-498 (2020-01-26)
Tumour cells frequently utilize glutamine to meet bioenergetic and biosynthetic demands of rapid cell growth. However, glutamine dependence can be highly variable between in vitro and in vivo settings, based on surrounding microenvironments and complex adaptive responses to glutamine deprivation.
Xiaofeng Guo et al.
Molecular cancer, 19(1), 83-83 (2020-05-08)
Accumulating evidence suggests that circular RNAs (circRNAs) are important participants in cancer progression. However, the biological processes and underlying mechanisms of circRNAs in pancreatic ductal adenocarcinoma (PDAC) are unclear. CircRNAs were verified by Sanger sequencing. Colony formation, 5-Ethynyl-2'-deoxyuridine (EdU), and
Bryan Frey et al.
Journal of neurochemistry, 157(4), 872-888 (2020-08-11)
Bimolecular fluorescence complementation (BiFC) was introduced a decade ago as a method to monitor alpha-synuclein (α-syn) oligomerization in intact cells. Since then, several α-syn BiFC cellular assays and animal models have been developed based on the assumption that an increase
Koichi Ogura et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(4), 1184-1194 (2020-11-25)
Desmoplastic small round cell tumor (DSRCT) is a highly lethal intra-abdominal sarcoma of adolescents and young adults. DSRCT harbors a t(11;22)(p13:q12) that generates the EWSR1-WT1 chimeric transcription factor, the key oncogenic driver of DSRCT. EWSR1-WT1 rewires global gene expression networks
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej